PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsGadoterate meglumine
Gadoterate meglumine
Clariscan, Dotarem, Gadoterate Meglumine (gadoterate meglumine) is a small molecule pharmaceutical. Gadoterate meglumine was first approved as Dotarem on 2013-03-20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Clariscan, Dotarem, Gadoterate meglumine
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gadoterate meglumine
Tradename
Company
Number
Date
Products
DOTAREMGuerbetN-204781 RX2013-03-20
5 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
clariscanANDA2024-09-17
dotaremNew Drug Application2025-03-14
gadoterate meglumineANDA2024-10-27
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V08: Contrast media
— V08C: Magnetic resonance imaging contrast media
— V08CA: Paramagnetic contrast media
— V08CA02: Gadoteric acid
HCPCS
Code
Description
A9575
Injection, gadoterate meglumine, 0.1 ml
Clinical
Clinical Trials
50 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast diseasesD001941—N60-N651——1—2
Magnetic resonance imagingD008279—————112
Coronary artery diseaseD003324—I25.1———112
Renal insufficiencyD051437—N19———2—2
CognitionD003071EFO_0003925————1—1
Hepatocellular carcinomaD006528—C22.0———1—1
Liver neoplasmsD008113EFO_1001513C22.0———1—1
Type 2 diabetes mellitusD003924EFO_0001360E11———1—1
Diabetes mellitusD003920EFO_0000400E08-E13———1—1
Myocardial ischemiaD017202EFO_1001375I20-I25———1—1
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cerebral arterial diseasesD002539EFO_1000859———2——2
Central nervous system diseasesD002493—G96.9——1——1
Nervous system diseasesD009422—G00-G99——1——1
Self-assessmentD012647————1——1
Diagnostic self evaluationD059026————1——1
Kidney diseasesD007674EFO_0003086N08——1——1
Retinal diseasesD012164—H35.9——1——1
Renal artery obstructionD012078EFO_1001150N28.0——1——1
Brain neoplasmsD001932EFO_0003833C71——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501————1
FibroadenomaD018226——1————1
Chronic kidney failureD007676EFO_0003884N18.61————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial perfusion imagingD055414——————11
Brain diseasesD001927—G93.40————11
CardiomyopathiesD009202EFO_0000318I42————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGadoterate meglumine
INN—
Description
Gadoteric acid, sold under the brand name Dotarem among others, is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (gadoterate meglumine). The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because it has magnetic properties, gadoteric acid develops a magnetic moment when put under a magnetic field, which increases the signal intensity (brightness) of tissues during MRI imaging.
Classification
Small molecule
Drug classgadolinium derivatives (principally for diagnostic use)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID72573-82-1
RxCUI—
ChEMBL IDCHEMBL2219415
ChEBI ID73727
PubChem CID158536
DrugBankDB09132
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,763 documents
View more details
Safety
Black-box Warning
Black-box warning for: Clariscan, Dotarem, Gadoterate meglumine
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,149 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use